3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2729
Lung Neoplasms
945
Small Cell Lung Carcinoma
447
Neoplasms
419
Colorectal Neoplasms
409
Breast Neoplasms
355
Melanoma
332
Ovarian Neoplasms
316
Neoplasm Metastasis
281
Pancreatic Neoplasms
252
Squamous Cell Carcinoma of Head and Neck
232
Stomach Neoplasms
227
Carcinoma, Renal Cell
214
Triple Negative Breast Neoplasms
190
Head and Neck Neoplasms
178
Prostatic Neoplasms
152
Esophageal Neoplasms
149
Endometrial Neoplasms
145
Uterine Cervical Neoplasms
139
Urinary Bladder Neoplasms
132
Mesothelioma
115
Carcinoma
106
Colonic Neoplasms
104
Carcinoma, Hepatocellular
104
Sarcoma
99
Carcinoma, Transitional Cell
99
Kidney Neoplasms
74
Mesothelioma, Malignant
72
Cholangiocarcinoma
67
Liver Neoplasms
66
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metatropic dwarfism
×
Thoracic
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts